GlassScriptPhysician profile
Harry L Wadsworth
NPI 1144213265
$6,434.58
in general payments reported to CMS, 2019-2025
49 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,225 · 2020: $718 · 2021: $1,941 · 2022: $1,593 · 2023: $908 · 2024: $49.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $957.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $858.30 | 2019-2023 | Evusheld, Flumist Quadrivalent, Farxiga |
| Lilly USA, LLC | $619.16 | 2019-2023 | Mounjaro, Trulicity |
| Novo Nordisk INC | $572.56 | 2020-2023 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $548.28 | 2019-2024 | Ubrelvy, Vraylar, Linzess |
| Amgen INC. | $417.74 | 2019-2023 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.85 | 2019-2022 | |
| Amarin Pharma, INC. | $255.24 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $251.08 | 2019-2022 | |
| Abbott Laboratories | $239.64 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $193.90 | 2021 | |
| Horizon Therapeutics Plc | $188.56 | 2019-2023 | Krystexxa |
| Merck Sharp & Dohme LLC | $174.75 | 2020-2023 | Verquvo, Steglatro, Belsomra |
| Janssen Biotech, INC. | $170.98 | 2019-2021 | |
| Pfizer INC. | $152.33 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $129.65 | 2019-2023 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Wadsworth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.